Stock Scorecard
Stock Summary for TG Therapeutics Inc (TGTX) - $36.50 as of 10/8/2025 3:22:47 PM EST
Total Score
11 out of 30
Safety Score
49 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TGTX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TGTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TGTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TGTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for TGTX (49 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 6 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 5 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 2 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for TGTX
Financial Details for TGTX
Company Overview |
|
|---|---|
| Ticker | TGTX |
| Company Name | TG Therapeutics Inc |
| Country | USA |
| Description | TG Therapeutics, Inc. (TGTX) is a leading commercial-stage biopharmaceutical company based in New York, specializing in the development and commercialization of innovative therapies for B-cell malignancies and autoimmune disorders. The company’s robust pipeline includes multiple product candidates that leverage advanced drug development technologies, positioning it as a key player in the oncology and autoimmune therapeutic landscapes. With a strong commitment to addressing unmet medical needs, TG Therapeutics aims to enhance patient outcomes through its targeted treatments and ongoing clinical programs. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/30/2025 |
Stock Price History |
|
| Last Day Price | 36.50 |
| Price 4 Years Ago | 19.00 |
| Last Day Price Updated | 10/8/2025 3:22:47 PM EST |
| Last Day Volume | 1,556,020 |
| Average Daily Volume | 2,031,582 |
| 52-Week High | 46.48 |
| 52-Week Low | 21.27 |
| Last Price to 52 Week Low | 71.60% |
Valuation Measures |
|
| Trailing PE | 96.74 |
| Industry PE | 22.22 |
| Sector PE | 41.70 |
| 5-Year Average PE | 86.93 |
| Free Cash Flow Ratio | 45.06 |
| Industry Free Cash Flow Ratio | 14.45 |
| Sector Free Cash Flow Ratio | 30.25 |
| Current Ratio Most Recent Quarter | 3.86 |
| Total Cash Per Share | 0.81 |
| Book Value Per Share Most Recent Quarter | 1.90 |
| Price to Book Ratio | 21.04 |
| Industry Price to Book Ratio | 29.58 |
| Sector Price to Book Ratio | 32.02 |
| Price to Sales Ratio Twelve Trailing Months | 12.85 |
| Industry Price to Sales Ratio Twelve Trailing Months | 44.16 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.22 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 158,666,000 |
| Market Capitalization | 5,791,309,000 |
| Institutional Ownership | 64.56% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.72% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 325.00% |
| Annual Earnings Growth | 84.52% |
| Reported EPS 12 Trailing Months | 0.38 |
| Reported EPS Past Year | 0.20 |
| Reported EPS Prior Year | 0.14 |
| Net Income Twelve Trailing Months | 60,458,000 |
| Net Income Past Year | 23,383,000 |
| Net Income Prior Year | 12,672,000 |
| Quarterly Revenue Growth YOY | 92.10% |
| 5-Year Revenue Growth | 364.59% |
| Operating Margin Twelve Trailing Months | 24.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 129,126,000 |
| Total Cash Past Year | 179,894,000 |
| Total Cash Prior Year | 92,933,000 |
| Net Cash Position Most Recent Quarter | -115,911,000 |
| Net Cash Position Past Year | -64,535,000 |
| Long Term Debt Past Year | 244,429,000 |
| Long Term Debt Prior Year | 100,118,000 |
| Total Debt Most Recent Quarter | 245,037,000 |
| Equity to Debt Ratio Past Year | 0.48 |
| Equity to Debt Ratio Most Recent Quarter | 0.53 |
| Total Stockholder Equity Past Year | 222,364,000 |
| Total Stockholder Equity Prior Year | 160,502,000 |
| Total Stockholder Equity Most Recent Quarter | 276,432,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -59,237,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.37 |
| Free Cash Flow Past Year | -40,562,000 |
| Free Cash Flow Prior Year | -31,413,000 |
Options |
|
| Put/Call Ratio | 0.10 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 1.97 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 10/7/2025 10:51:23 AM EST |